格隆汇1月27日丨中国中药(00570.HK)公告，根据集团截至2025年12月31日止年度(「本期」)的未经审 核综合管理账目初步评估，预期集团(a)本期由盈转亏，亏损净额区间预计约为人民币3.5亿元至人民币5 亿元，上年同期溢利净额约为人民币2077万元；及(b)本期经调整溢利净额同比下降45%至55%，上年同 期约为人民币6.36亿元。 根据董事会目前可获得的资料，董事会认为：(a)集团本期由盈转亏主要原因为：(i)中药配方颗粒业务 受集采业务占比提高、市场竞争加剧等影响，收入规模及盈利能力下降；及(ii)本期商誉减值、无形资 产减值及信用减值增加；及(b)经调整溢利净额为扣除以下各项影响後的溢利净额：(i)商誉及相关资产 组减值；及(ii)部分附属公司补缴税款。 ...

步长制药2025年业绩预告：扭亏为盈背后的真实成色核心要点：财务表现：预计2025年归母净利润3... 步长制药2025年业绩预告：扭亏为盈背后的真实成色 核心要点： 财务表现：预计2025年归母净利润3.2亿-4.68亿元，实现扭亏为盈，2024年同期亏损5.54亿元；扣非净 利润5.9亿-8.68亿元 业务改善：药品销售规模同比增长，主要产品生产成本下降 会计因素：收购标的评估增值摊销于2024年末完成，摊销费用同比减少 关注重点：扣非净利润显著高于净利润，需关注商誉减值是否仍存隐患，以及核心业务真实增长质量 一次性因素主导的"扭亏" 步长制药（603858）交出了一份看似亮眼的业绩预告——从2024年亏损5.54亿元到2025年预计盈利3.2 亿-4.68亿元，实现扭亏为盈。但仔细拆解数据，这场"翻身仗"的含金量值得商榷。 最关键的转折点在于商誉减值的大幅收窄。2024年，公司计提了高达8.53亿元的商誉减值准备，而2025 年这一数字预计仅为1.6亿-2.38亿元，同比减少6.15亿-6.93亿元。换句话说，如果剔除商誉减值波动这 一会计科目的影响，公司的盈利改善幅度将大打折扣。 扭亏主因：商誉减值计 ...

Core Viewpoint - Harbin Weidi Electronics Co., Ltd. expects a significant decrease in net profit for 2025, projecting a range of 2.47 million to 3.70 million yuan, which represents a decline of 135.55 thousand to 258.55 thousand yuan compared to the previous year, equating to a year-on-year decrease of 26.81% to 51.14% [1] Group 1 - The company’s subsidiary, Anhui Alpha Silicon New Energy Common Technology Research Institute Co., Ltd., was acquired at the end of 2024, resulting in a goodwill of 25.48 million yuan on the balance sheet [1] - Preliminary assessments indicate that Alpha Silicon's operational performance is below expectations, and as of the announcement date, the financial data evaluation and audit procedures for Alpha Silicon have not been completed [1] - If the final evaluation and audit lead to a need for further goodwill impairment, it may result in the company’s net profit attributable to the parent company turning negative, introducing uncertainty [1] Group 2 - Should the net profit be negative, combined with the company’s projected operating revenue of less than 300 million yuan for the year, the company’s stock will face delisting risk warnings after the 2025 annual report is disclosed [1]

Core Viewpoint - Zhejiang Jibao Intelligent Equipment Co., Ltd. (hereinafter referred to as Jibao) is striving for an IPO on the Beijing Stock Exchange, facing significant challenges including declining profits and internal issues related to acquisitions and business performance [2][11]. Group 1: IPO and Shareholder Dynamics - Jibao's actual controllers, Shen Jiangyong and Chen Qun, signed a bet agreement with institutions, triggering a buyback clause if the company fails to submit an IPO application by December 31, 2025 [2]. - In December 2023, institutional investors such as Wanlin International and Hainan Shenggang invested in Jibao, but Wanlin International planned to exit shortly after due to changes in the domestic capital market [5][8]. - The company submitted its IPO application on December 25, 2025, and received acceptance from the Beijing Stock Exchange on December 30, 2025 [8]. Group 2: Financial Performance - Jibao's revenue grew from 250 million yuan in 2022 to 356 million yuan in 2024, but net profit declined from approximately 46.79 million yuan in 2022 to about 38.90 million yuan in 2024, marking a decrease of 8.21% in 2023 [11][15]. - The company reported a goodwill impairment of approximately 14.85 million yuan in 2023 due to the underperformance of its acquired subsidiary, Qiaohong Machinery, which saw its net profit drop significantly [15][16]. - The gross margin for Jibao's main products has been declining, with the gross margin for machine tool auxiliary equipment dropping from 25.82% in 2022 to 15.50% in the first half of 2025 [19]. Group 3: Cost Control Measures - Jibao has been actively controlling costs, with R&D expenses consistently below the industry average, hovering around 4% to 5% [21]. - The company has employed a significant number of retired personnel, accounting for over 12% of its total workforce, which helps reduce costs in the short term [21].

Group 1 - The company expects a net loss for the fiscal year 2025, with the performance forecast period from January 1, 2025, to December 31, 2025 [1] - The anticipated decline in net profit attributable to shareholders is primarily due to goodwill impairment related to the previously acquired assets in the live streaming, VOIP, and IPTV business segments [2] - The financial data provided is a preliminary estimate from the company's finance department and has not yet been audited by the accounting firm [3] Group 2 - The goodwill impairment testing is still ongoing, and the impact of the impairment on the 2025 operating performance is based on preliminary calculations [3] - The company emphasizes the importance of cautious decision-making for investors due to the potential risks associated with the anticipated financial performance [3]

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 证券代码：688350 证券简称：富淼科技 公告编号：2026-009 转债代码：118029 转债简称：富淼转债 江苏富淼科技股份有限公司 2025年年度业绩预告 （一）业绩预告期间 2025年1月1日至2025年12月31日。 （二）业绩预告情况 1.经江苏富淼科技股份有限公司（以下简称"公司"）财务部门初步测算，预计2025年年度实现归属于母 公司所有者的净利润与上年同期（法定披露数据）相比，将实现扭亏为盈，实现归属于母公司所有者的 净利润1,280.00万元到1,900.00万元。 2.归属于母公司所有者扣除非经常性损益后的净利润1,100.00万元到1,650.00万元。 （三）本次业绩预告相关财务数据未经注册会计师审计。 二、上年同期业绩情况 （一）利润总额：-1,186.18万元；归属于母公司所有者的净利润：-465.45万元；归属于母公司所有者的 扣除非经常性损益的净利润：-1,260.5 ...

Core Viewpoint - Chutian Technology (300358) reports that the operational status of ROMACO Group is improving steadily compared to 2024, with business operations and quality on the rise [1] Group 1: Operational Performance - The management team of the German ROMACO Group has been adjusted and optimized, leading to gradual improvements in operational status [1] - Core business indicators and market competitiveness have increased compared to the same period last year, supporting the stability of goodwill [1] Group 2: Goodwill Assessment - The final determination of whether goodwill will be impaired and the amount of impairment will depend on the formal goodwill impairment test report issued by a third-party asset appraisal company and auditing agency [1] - Specific details will be disclosed in future announcements by the company [1]

（记者 王晓波） 每经AI快讯，达嘉维康1月26日晚间发布业绩预告，预计2025年归属于上市公司股东的净利润亏损2.5亿 元~3亿元，同比由盈转亏。业绩变动主要原因是，报告期内，连锁药房行业整体面临宏观市场环境变 化及竞争压力加剧，叠加行业政策调整、消费习惯变迁等多重因素，公司连锁药房板块业绩出现阶段性 下滑；报告期内，前期收购的子公司受上述行业环境、自身经营及业务整合等因素影响，实际经营业绩 未达收购时预期，基于审慎性财务评估原则，公司对相关子公司收购形成的商誉进行减值测试，并计提 相应商誉减值准备，导致本期资产减值损失金额较大，对当期利润构成显著影响。 每经头条（nbdtoutiao）——国际金价冲破5000美元！7年涨了280%，什么时候才见顶？专家：关键还 看美元，重点关注国际货币体系、降息和科技革命 ...

达嘉维康公告，预计2025年度净利润亏损2.5亿元-3亿元，上年同期净利润2657.49万元。报告期内，连 锁药房行业整体面临宏观市场环境变化及竞争压力加剧，叠加行业政策调整、消费习惯变迁等多重因 素，公司连锁药房板块业绩出现阶段性下滑；前期收购的子公司受上述行业环境、自身经营及业务整合 等因素影响，实际经营业绩未达收购时预期，基于审慎性财务评估原则，公司对相关子公司收购形成的 商誉进行减值测试，并计提相应商誉减值准备，导致本期资产减值损失金额较大，对当期利润构成显著 影响。 ...

南财智讯1月26日电，楚天科技在投资者关系活动中表示，子公司德国ROMACO集团经管理团队调整优 化及业务协同深化后，经营状况逐步改善，核心业务指标及市场竞争力较2024年同期有所提升，为商誉 稳定性提供了支撑；最终商誉是否发生减值及减值金额，仍需以第三方资产评估机构及审计机构出具的 正式商誉减值测试报告为准，具体以公司后续披露的相关公告信息为准。 ...